Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov:77:53-63.
doi: 10.1016/j.bpobgyn.2021.09.003. Epub 2021 Sep 15.

Misoprostol for labour induction

Affiliations
Review

Misoprostol for labour induction

Nimisha Kumar et al. Best Pract Res Clin Obstet Gynaecol. 2021 Nov.

Abstract

Oral and vaginal misoprostol are effective induction methods, but there is a delicate balance between a quicker labour and avoiding side effects. In randomised comparisons with balloon catheters, oral misoprostol resulted in more vaginal births in the first 24 h as well as fewer caesarean sections without an increase in hyperstimulation events. Vaginal misoprostol was most effective when used concurrently with a balloon catheter. In comparison with dinoprostone, oral misoprostol had lower rates of caesarean section and uterine hyperstimulation with foetal heart rate changes, but fewer babies were born vaginally within 24 h. In contrast, vaginal misoprostol resulted in more vaginal births within 24 h, with no significant differences in caesarean section rates. There were no differences in perinatal adverse events with either route. When oral and vaginal misoprostol were compared, vaginal misoprostol resulted in more vaginal births in the first 24 h, but with more maternal and neonatal complications.

Keywords: Induction; Labour; Misoprostol; Obstetrics.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors of this paper were also the authors of the cited Cochrane review entitled ‘Low-dose oral misoprostol for induction of labour’. ADW is a scientific advisor to Norgine, maker of oral misoprostol. The University of Liverpool is paid for his time, but he receives no personal payments for this. DMH and ADW are authors on two of the cited trials.

Similar articles

Cited by

LinkOut - more resources